Clinical Trial Update: Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Epstein-Barr Virus (EBV) immune T-lymphocytes from a normal HLA-compatible donor for EBV-related lymphoproliferative disorders…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-associated Malignancies
• Ebv-induced Lymphomas
• Transplant Patients with Ebv Viremia At High Risk For Developing Recurrent Ebv Lymphoma

Drugs mentioned

• EBV-specific T-lymphocytes (allogeneic), such as EBV-CTLs (EBV-specific T-lymphocytes)

Snippet

Sponsor: Atara Biotherapeutics | Conditions: EBV-induced Lymphomas, EBV-associated Malignancies | Phase 2 | Status: COMPLETED | Results posted: 2022-10-21